Skip to main content

Table 2 Univariable and multivariable analysis for PSA progression-free survival in patients with mHSPC treated with ADT

From: Impact of early changes in serum biomarkers following androgen deprivation therapy on clinical outcomes in metastatic hormone-sensitive prostate cancer

     

Multivariable

  

Univariable

Model I (Base line PSA adjusted) (n = 52; chi-square 45.5; AIC 229.7)

Model II (n = 52; chi-square 13.2; AIC 234.7)

Factors

Group

HR

95% CI

p value

HR

95% CI

p value

HR

95% CI

p value

Age

Continuous

0.99

0.95–1.03

0.642

      

ECOG-PS

1 vs 0

1.13

0.40–3.17

0.820

      

Log-transformed baseline PSA level (ng/dL)

Continuous

1.14

0.95–1.36

0.156

3.62

1.57–8.36

0.003

   

Baseline Hb level (g/dl)

Low vs normal

3.31

1.68–6.51

0.001

      

Baseline ALP level (IU/l)

High vs normal

1.58

0.84–2.972

0.157

      

Baseline LDH level (IU/l)

High vs normal

1.23

0.66–2.29

0.510

      

Presence of bone pain

Yes vs No

1.52

0.81–2.84

0.191

      

Biopsy Gleason score

≥8 vs ≤7

2.60

0.62–10.82

0.190

      

Visceral metastasis

Yes vs No

28.62

4.03–203.21

0.001

      

EOD score

≥3 vs ≤2

3.89

1.91–7.92

<0.001

3.14

1.45–6.82

0.004

3.47

1.65–7.33

0.001

Sub-group in the CHAARTED trial

high vs low

2.44

1.28–4.65

0.007

      

Log-transformed PSA change (baseline-12wks)

Continuous

1.10

0.92–1.32

0.281

0.30

0.13–0.68

0.004

1.04

0.87–1.25

0.66

Hb level at 12 weeks

Low vs normal

1.94

1.02–3.67

0.043

      

ALP level at 12 weeks

High vs normal

3.19

1.67–6.11

0.001

      

LDH level at 12 weeks

High vs normal

1.17

0.59–2.31

0.652

      
  1. mHSPC metastatic hormone-sensitive prostate cancer, ADT androgen deprivation therapy, ECOG Eastern Cooperative Oncology Group, PSA prostate specific antigen, Hb hemoglobin, ALP Alkaline phosphatase, LDH Lactate dehydrogenase, EOD extend of bone metastasis, HR hazard ratio, CI confidence interbal